BACKGROUND: We aimed to identify clinical significance of latent membrane protein 1 (LMP1), Ki-67, cyclin-B1, and epidermal growth factor receptor (EGFR), in nonendemic nasopharyngeal carcinoma (NPC). METHODS: The relation between expression of the markers in 45 NPC specimens and clinicopathological and survival variables was statistically analyzed. RESULTS: LMP1 was present in 33% of the tumors, and its presence was associated with advanced nodal and disease stages. Overexpression was defined as labeling index > or = median value for Ki-67, > or = 15% for cyclin-B1, and > or =50% for EGFR, and it was displayed in 50%, 55%, and 80% of the specimens, respectively. Strong EGFR staining intensity and not overexpression of the 3 markers was the variable with statistically significant impact on treatment outcomes in terms of worse local and locoregional tumor control rates. CONCLUSIONS: Our results suggest that the evaluation of EGFR staining intensity in patients with NPC may identify a subgroup of patients with poor prognosis.
BACKGROUND: We aimed to identify clinical significance of latent membrane protein 1 (LMP1), Ki-67, cyclin-B1, and epidermal growth factor receptor (EGFR), in nonendemic nasopharyngeal carcinoma (NPC). METHODS: The relation between expression of the markers in 45 NPC specimens and clinicopathological and survival variables was statistically analyzed. RESULTS:LMP1 was present in 33% of the tumors, and its presence was associated with advanced nodal and disease stages. Overexpression was defined as labeling index > or = median value for Ki-67, > or = 15% for cyclin-B1, and > or =50% for EGFR, and it was displayed in 50%, 55%, and 80% of the specimens, respectively. Strong EGFR staining intensity and not overexpression of the 3 markers was the variable with statistically significant impact on treatment outcomes in terms of worse local and locoregional tumor control rates. CONCLUSIONS: Our results suggest that the evaluation of EGFR staining intensity in patients with NPC may identify a subgroup of patients with poor prognosis.
Authors: Xiu Juan Cao; Jun Fang Hao; Xin Hua Yang; Peng Xie; Lan Ping Liu; Chun Ping Yao; Jin Xu Journal: Med Oncol Date: 2011-01-08 Impact factor: 3.064
Authors: Alexander A Benders; Weihua Tang; Jaap M Middeldorp; Astrid E Greijer; Leigh B Thorne; William K Funkhouser; W Kimryn Rathmell; Margaret L Gulley Journal: Head Neck Pathol Date: 2009-11-12
Authors: Vivian Wai Yan Lui; Cecilia Pik Yuk Lau; Kakiu Ho; Margaret Heung Ling Ng; Suk Hang Cheng; Sai-Wah Tsao; Chi Man Tsang; Kenny Ieng Kit Lei; Anthony Tc Chan; Tony Shu Kam Mok Journal: Invest New Drugs Date: 2010-06-23 Impact factor: 3.850